ArticlePloS one2025

Tislelizumab plus chemotherapy versus chemotherapy as first-line treatment for extensive-stage small cell lung cancer: A cost-effectiveness analysis.

Zhiwei Zheng et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.